

6 June 2025

ASX Announcement

Withdrawal of Share Placement

Firebrick Pharma Limited (ASX:FRE) (**Company** or **Firebrick**) refers to its request for a trading halt lodged on 5 June 2025.

The Board has decided not to proceed with the proposed share placement at this time.

This announcement has been authorised for release by the Board of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick recently introduced Nasodine in the United States, Singapore and Fiji and South Pacific, with an agreement in place to also manufacture and launch Nasodine in the Philippines.

Media enquiries:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com